Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1996 1
1998 1
1999 2
2005 1
2007 3
2008 1
2009 1
2010 3
2011 3
2012 2
2013 1
2014 2
2015 2
2016 1
2017 3
2018 4
2019 5
2020 8
2021 7
2022 2
2023 9
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

57 results

Results by year

Filters applied: . Clear all
Page 1
[(18)F]-Fludarabine for Hematological Malignancies.
Barré L, Hovhannisyan N, Bodet-Milin C, Kraeber-Bodéré F, Damaj G. Barré L, et al. Front Med (Lausanne). 2019 Apr 17;6:77. doi: 10.3389/fmed.2019.00077. eCollection 2019. Front Med (Lausanne). 2019. PMID: 31058154 Free PMC article. Review.
In DLBCL patients, increased uptake was observed in sites considered abnormal by CT and [(18)F]FDG; in two patients discrepancies were observed in comparison with (18)F-FDG. ...Moreover, its mean effective dose was below the effective dose reported for (18)F- …
In DLBCL patients, increased uptake was observed in sites considered abnormal by CT and [(18)F]FDG; in two patients discrepancies wer …
New Developments in Myeloma Treatment and Response Assessment.
Kraeber-Bodéré F, Jamet B, Bezzi D, Zamagni E, Moreau P, Nanni C. Kraeber-Bodéré F, et al. J Nucl Med. 2023 Sep;64(9):1331-1343. doi: 10.2967/jnumed.122.264972. Epub 2023 Aug 17. J Nucl Med. 2023. PMID: 37591548 Free PMC article.
Over the past decade, new morphologic or hybrid imaging techniques have gradually replaced conventional skeletal surveys. PET/CT using (18)F-FDG is a powerful imaging tool for the workup at diagnosis and for therapeutic evaluation allowing medullary and extramedullary asse …
Over the past decade, new morphologic or hybrid imaging techniques have gradually replaced conventional skeletal surveys. PET/CT using (18) …
2-[ 18 F]FDG PET/CT Flare-up Phenomena Following T-Cell Engager Bispecific Antibody in Multiple Myeloma.
Jamet B, Bodet-Milin C, Moreau P, Kraeber-Bodéré F, Touzeau C. Jamet B, et al. Clin Nucl Med. 2023 May 1;48(5):e230-e231. doi: 10.1097/RLU.0000000000004588. Epub 2023 Mar 6. Clin Nucl Med. 2023. PMID: 36881609
T-cell-redirecting bispecific antibodies represent a new standard of care for the treatment of triple-class refractory myeloma patients. Here, 2-[ 18 F]FDG PET/CT imaging was performed on a 61-year-old woman with relapsed myeloma to determine metabolic response to talqueta …
T-cell-redirecting bispecific antibodies represent a new standard of care for the treatment of triple-class refractory myeloma patients. Her …
Hybrid simultaneous whole-body 2-[(18)F]FDG-PET/MRI imaging in newly diagnosed multiple myeloma: first diagnostic performance and clinical added value results.
Jamet B, Carlier T, Bailly C, Bodet-Milin C, Monnet A, Frampas E, Touzeau C, Moreau P, Kraeber-Bodere F. Jamet B, et al. Eur Radiol. 2023 Sep;33(9):6438-6447. doi: 10.1007/s00330-023-09593-1. Epub 2023 Apr 6. Eur Radiol. 2023. PMID: 37022439
OBJECTIVES: Mixing diagnostic and prognostic data provided by whole-body MRI (WB-MRI) and 2-(18)F-fluorodeoxyglucose (2-[(18)F]FDG) positron emission tomography (2-[(18)F]FDG-PET) from a single simultaneous imaging technique for newly diagnosed multiple myelo …
OBJECTIVES: Mixing diagnostic and prognostic data provided by whole-body MRI (WB-MRI) and 2-(18)F-fluorodeoxyglucose (2-[(18)F …
Radioimmunotherapy of Non-Hodgkin B-cell Lymphoma: An update.
Cicone F, Santo G, Bodet-Milin C, Cascini GL, Kraeber-Bodéré F, Stokke C, Kolstad A. Cicone F, et al. Semin Nucl Med. 2023 May;53(3):413-425. doi: 10.1053/j.semnuclmed.2022.12.006. Epub 2023 Jan 10. Semin Nucl Med. 2023. PMID: 36635112 Review.
(18)F-Fludarabine PET for Lymphoma Imaging: First-in-Humans Study on DLBCL and CLL Patients.
Chantepie S, Hovhannisyan N, Guillouet S, Pelage JP, Ibazizene M, Bodet-Milin C, Carlier T, Gac AC, Réboursière E, Vilque JP, Kraeber-Bodéré F, Manrique A, Damaj G, Leporrier M, Barré L. Chantepie S, et al. J Nucl Med. 2018 Sep;59(9):1380-1385. doi: 10.2967/jnumed.117.206920. Epub 2018 Feb 1. J Nucl Med. 2018. PMID: 29419478 Free article. Clinical Trial.
This was the first-in-humans clinical study of (18)F-fludarabine, which is a radiopharmaceutical for PET imaging in lymphoma, for which many issues remain controversial with the standard radiotracer (18)F-FDG. ...Nonetheless, the comparison of (18)F-fludarabi …
This was the first-in-humans clinical study of (18)F-fludarabine, which is a radiopharmaceutical for PET imaging in lymphoma, for whi …
Prognostic Value of (18)F-FDG PET Radiomics Features at Baseline in PET-Guided Consolidation Strategy in Diffuse Large B-Cell Lymphoma: A Machine-Learning Analysis from the GAINED Study.
Carlier T, Frécon G, Mateus D, Rizkallah M, Kraeber-Bodéré F, Kanoun S, Blanc-Durand P, Itti E, Le Gouill S, Casasnovas RO, Bodet-Milin C, Bailly C. Carlier T, et al. J Nucl Med. 2024 Jan 2;65(1):156-162. doi: 10.2967/jnumed.123.265872. J Nucl Med. 2024. PMID: 37945379
The results of the GA in Newly Diagnosed Diffuse Large B-Cell Lymphoma (GAINED) study demonstrated the success of an (18)F-FDG PET-driven approach to allow early identification-for intensification therapy-of diffuse large B-cell lymphoma patients with a high risk of relaps …
The results of the GA in Newly Diagnosed Diffuse Large B-Cell Lymphoma (GAINED) study demonstrated the success of an (18)F-FDG PET-dr …
(18)F-FDG PET/CT in multiple myeloma: critical insights and future directions.
Bailly C, Carlier T, Jamet B, Touzeau C, Moreau P, Kraeber-Bodéré F, Bodet-Milin C. Bailly C, et al. Eur J Nucl Med Mol Imaging. 2019 May;46(5):1048-1050. doi: 10.1007/s00259-019-04279-7. Epub 2019 Feb 15. Eur J Nucl Med Mol Imaging. 2019. PMID: 30770949 No abstract available.
Molecular Signature of (18)F-FDG PET Biomarkers in Newly Diagnosed Multiple Myeloma Patients: A Genome-Wide Transcriptome Analysis from the CASSIOPET Study.
Alberge JB, Kraeber-Bodéré F, Jamet B, Touzeau C, Caillon H, Wuilleme S, Béné MC, Kampfenkel T, Sonneveld P, van Duin M, Avet-Loiseau H, Corre J, Magrangeas F, Carlier T, Bodet-Milin C, Chérel M, Moreau P, Minvielle S, Bailly C. Alberge JB, et al. J Nucl Med. 2022 Jul;63(7):1008-1013. doi: 10.2967/jnumed.121.262884. Epub 2022 Jan 27. J Nucl Med. 2022. PMID: 35086897 Free PMC article.
The International Myeloma Working Group recently fully incorporated (18)F-FDG PET into multiple myeloma (MM) diagnosis and response evaluation. ...Methods: Reported prognostic biomarkers ((18)F-FDG avidity, SUV(max), number of focal lesions, presence of paramedullar …
The International Myeloma Working Group recently fully incorporated (18)F-FDG PET into multiple myeloma (MM) diagnosis and response e …
57 results